LCMV clone 13 culture supernatant. This Lymphocytic choriomeningitis virus[Clone 13] is preserved under Viral Storage Medium -80C. Tests for the presence of mycoplasmae were not performed. To confirm its identity the virus has been fully sequenced.
HIV-1 variant, infectious recombinant virus with specific mutations in the protease gene as indicated. These mutations confer resistance to specific HIV protease inhibitors and have been reported for emerging virus in vivo.
Plasmid containing an NL4-3 based HIV-1 genome with a big deletion between SalI site (5785) and XhoI site (8887), leading to a deletion of the viral genes vpu,env, tat, rev. Also the "rev-response-element" RRE is missing, leading to a lack of expression also of the gag-pol genes
Gp41 recombinant, carrying the "MIF" motif, typical for subtype AE, in the fusion domain of the subtype B prototype NL4-3 - for studying the fusion function
Gp41 recombinant, carrying the "MIF" motif, typical for subtype AE, in the fusion domain of the subtype B prototype NL4-3 - for studying the fusion function.
HIV-1 variant, infectious recombinant virus with specific mutations in the RT gene as indicated. These mutations confer resistance to specific HIV RT inhibitors and have been reported for emerging virus in vivo.
HIV-1 variant, infectious recombinant virus with specific mutations in the RT gene as indicated. These mutations confer resistance to specific HIV RT inhibitors and have been reported for emerging virus in vivo.
HIV-1 variant, infectious recombinant virus with specific mutations in the RT gene as indicated. These mutations confer resistance to specific HIV RT inhibitors and have been reported for emerging virus in vivo.
Plasmid contains the entire genome of HIV-1 with specific mutations in the reverse transcriptase gene, which can confer drug resistance to specific HIV-1 inhibitors. The respective mutations have been reported in viruses from HIV-infected individuals on reverse transcriptase inhibitors with virologic therapy failure.
Plasmid contains the entire genome of HIV-1 with specific mutations in the reverse transcriptase gene, which can confer drug resistance to specific HIV-1 inhibitors. The respective mutations have been reported in viruses from HIV-infected individuals on reverse transcriptase inhibitors with virologic therapy failure.
This recombinant HIV-1 variant contains a common polymorphism, which has been described as increasing viral replication in the presence of fitness-reducing Pr mutations
HIV-1 variant, infectious recombinant virus with specific mutations in the protease gene as indicated. These mutations confer resistance to specific HIV protease inhibitors and have been reported for emerging virus in vivo.
HIV-1 variant, infectious recombinant virus with specific mutations in the protease gene as indicated. These mutations confer resistance to specific HIV protease inhibitors and have been reported for emerging virus in vivo.
Yes, we also use cookies on this site to enhance your user experience
By clicking the Accept button, you agree to us doing so for all our categories of cookies.
Strictly necessary cookies for our website to be able to operate or to provide you with essential services such as connecting to your account on this website.
Cookies that mainly permit to remember settings you have applied. They help our site to work well and enable additional features which can make your user experience better.
Cookies that permit to use the social media sharing buttons on our Website.
Cookies to measure the visits on our Website and permit to analyze how the Website is accessed, used, or is performing.
